Portfolio Design Labs LLC Purchases Shares of 4,281 Stryker Corporation $SYK

Portfolio Design Labs LLC acquired a new stake in shares of Stryker Corporation (NYSE:SYK) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,281 shares of the medical technology company’s stock, valued at approximately $1,348,000.

Several other large investors have also modified their holdings of the stock. Sankala Group LLC purchased a new stake in Stryker in the fourth quarter valued at approximately $26,000. Godfrey Financial Associates Inc. acquired a new position in Stryker during the fourth quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new position in Stryker during the third quarter worth approximately $27,000. Atlas Capital Advisors Inc. acquired a new position in shares of Stryker in the 4th quarter valued at $27,000. Finally, Gables Capital Management Inc. acquired a new position in shares of Stryker in the 2nd quarter valued at $25,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on SYK shares. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Citigroup reissued a “buy” rating on shares of Stryker in a research report on Thursday, August 13th. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a research note on Friday, May 1st. Evercore set a $350.00 price objective on Stryker in a report on Monday, July 6th. Finally, UBS Group started coverage on Stryker in a research note on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Stock Down 3.5%

Shares of NYSE SYK opened at $327.97 on Friday. The firm has a market cap of $125.80 billion, a price-to-earnings ratio of 33.99, a PEG ratio of 2.17 and a beta of 0.76. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock’s 50-day simple moving average is $326.64 and its 200-day simple moving average is $332.66.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the previous year, the business earned $3.13 EPS. Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

Insider Transactions at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 665,370 shares of company stock valued at $216,238,501. Insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.